Cargando...
Tremelimumab-Induced Graves Hyperthyroidism
Tremelimumab and ipilimumab are monoclonal antibodies directed against the extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and have been used as immunotherapies against immune checkpoints that suppress T-cell activation. Anti-CTLA-4 antibody-based therapies have been sho...
Guardado en:
| Publicado en: | Eur Thyroid J |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
S. Karger AG
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527187/ https://ncbi.nlm.nih.gov/pubmed/28785544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000464285 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|